1. Time Since SARS-CoV-2 Infection and Humoral Immune Response Following BNT162b2 mRNA Vaccination
- Author
-
A.H. Ayesha Lavell, Lonneke A. van Vught, Melissa Oomen, Khadija Tejjani, Hcw, Judith A. Burger, Michiel Schinkel, Karlijn van der Straten, Marleen A. Slim, Marit J. van Gils, Marije K. Bomers, Jonne J. Sikkens, Rogier W. Sanders, Alexander P.J. Vlaar, Meliawati Poniman, Yvo M. Smulders, Joost Wiersinga, and Brent Appelman
- Subjects
Vaccination ,Titer ,Messenger RNA ,Immune system ,business.industry ,Informed consent ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Immunology ,Medicine ,business ,Antigen binding ,Neutralization - Abstract
Background: To optimise the use of available SARS-CoV-2 vaccines, some advocate delaying second vaccination for individuals infected within six months. We studied whether post-vaccination immune response is equally potent in individuals infected over six months prior to vaccination. Methods: We tested serum IgG binding to SARS-CoV-2 spike protein and neutralising capacity in 110 healthcare workers, before and after both BNT162b2 messenger RNA (mRNA) vaccinations. We compared outcomes between participants with more recent infection (n=18, median two months, IQR 2-3), with infection-vaccination interval over six months (n=19, median nine months, IQR 9-10), and to those not previously infected (n=73). Findings: Both recently and earlier infected participants showed comparable humoral immune responses after a single mRNA vaccination, while exceeding those of previously uninfected persons after two vaccinations with 2·5 fold (p=0·003) and 3·4 fold (p
- Published
- 2021
- Full Text
- View/download PDF